Member Info for technick

... we are now selling in the US with one of the largest automated platform providers in the world.

I don't think DB has much choice other than to find a trade sale now, the share price will rise on news and sales now, probably to £1.50-£2.00 over the next 3-5 months, then what? Better to sell now than wait?

longterm, £100m+ sale, I'd probably go for it

dots says over 50% of people will have to wait until 2022 for vaccination, if people only have 3-6 months protection surely it means by that time 50% who were vaccinated will not then be protected, and so the cycle repeats. Thats without considering new variants which we've been banging on about for months on this BB! Testing here for years and years and years!

For Danaher it's a no brainer, GDR retain 60% of the margin, if Cytiva manufacture and Beckman provide a sales channel / complete system, Danaher will want that 60% margin

Agree, market cap now clearly out of kilter with the commercial position, not much of the COVID angle is priced in here so should see significant rise in market cap over the coming months. Wouldn't rule out a Beckman trade sale in the new year.

1 Beckman machine £1.5m pa profit, 10 machines £15m pa, 100 machines £150m profit pa... This is how our sales scale here!

Haha, yeah, no. It's not a black and white decision and DB would have waited until he was sure of approval and to build up stock. Beckman also only just rolling out to a wider market. They will hit the ground running now.

for context, if each Biomek can process 1000 tests per day, thats £10k sales to GDR, £6k profit - £1.5m profit per year on a 5 day week...

"in order to support the Beckman Biomek system's transition into clinical use and exploit commercial opportunities, the product needs to be commercially available in the United States to end users."

Clear that this is an important partnership between GDR and Beckman, should see some positive new flow around availability from Beckman too

They must have had positive feedback from FDA about the pending authorisation, DB clearly chose to wait

... great news here, sales will come now.

It had been higher in terms of burn rate as they built up stocks of raw reagents for production. It had been £750k per month but was reduced to £400k per month once those stock securities were established. I suspect the Ukraine stock is finished, and we will hear about the supply in due course.... 1.2m tests at £10 is low double digit. Seems to stack up. The order is contingent on funding to Ukraine which is probably where the delay is.... These things generally take longer to put into place and are not instant transactions due to the terms

I hope this is the GDR test, the numbers match up, DB needs a break

Once those RNSs come this will move back up as the value of the sales become apparent. It needs a Beckman partner in the US, is needs FDA to fly. Im not sure what's holding up the Ukraine deployment. That alone could be a significant chunk of a £1 share price.

I tend to agree, if everything aligns as it should them a £100m+ market cap is obtainable, I suspect an acquisition before that contingent on those FDA approvals!

The delay has been because the FDA wanted to approve the test for saliva and nasal swab samples as one application, initially the submission had been for swab only. Frustrating but ultimately better for GDR. Can't be long to go now.

Interestingly the Ukraine is highlighted as a country that won't ba able to vaccinate more the 10% of its population, relying instead on testing. I suspect a large part of this discussion is around pricing.

India. I suspect now waiting for FDA and WHO...

I agree Dave, trade sale on the horizon, its when not if

The conversion will probably have been planed to coincide with some news.... positive in that they want to convert, let's see what the coming weeks bring

Current broker note was 0.82p I believe, would be nice for them to update their figure

3,000 deaths in 24 hours, it's a poor state of affairs it really is